成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Cell Cycle/DNA Damage Anti-infection Autophagy
  2. DNA/RNA Synthesis Nucleoside Antimetabolite/Analog HSV Autophagy
  3. Cytarabine hydrochloride

Cytarabine hydrochloride  (Synonyms: 鹽酸阿糖胞苷; Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; Ara-C hydrochloride)

目錄號(hào): HY-13605A 純度: 99.67%
COA 產(chǎn)品使用指南 技術(shù)支持

Cytarabine hydrochloride 是一種核苷類似物,可引起 S 期細(xì)胞周期停滯并抑制 DNA聚合酶。Cytarabine 抑制 DNA 合成IC50 為 16 nM。Cytarabine hydrochloride 對(duì) HSV 具有抗病毒作用。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Cytarabine hydrochloride Chemical Structure

Cytarabine hydrochloride Chemical Structure

CAS No. : 69-74-9

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥550
In-stock
100 mg ¥500
In-stock
200 mg   詢價(jià)  
500 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Cytarabine hydrochloride:

MCE 顧客使用本產(chǎn)品發(fā)表的 62 篇科研文獻(xiàn)

WB

    Cytarabine hydrochloride purchased from MCE. Usage Cited in: Leukemia. 2021 Mar 29.  [Abstract]

    TF-1 clones are incubated with 2?μM Cytarabine (araC) for up to 10 or 12?h, and cleaved caspase-3 is detected by immunoblot analysis.

    查看 HSV 亞型特異性產(chǎn)品:

    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine hydrochloride has antiviral effects against HSV.

    IC50 & Target

    IC50: 16 nM (DNA synthesis)

    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    143B IC50
    16.88 μM
    Compound: Cytarabine
    Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
    Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay
    [PMID: 27073055]
    143B IC50
    2.06 μM
    Compound: Cytarabine
    Cytotoxicity against human 143B cells after 72 hrs by SRB assay
    Cytotoxicity against human 143B cells after 72 hrs by SRB assay
    [PMID: 27073055]
    A549 GI50
    0.2 μM
    Compound: Ara-C
    Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
    Growth inhibition of human A549 cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    A549 IC50
    0.83 μM
    Compound: ara-C
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    A549 IC50
    1.2 μM
    Compound: Ara-C
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    A549 IC50
    1.75 μM
    Compound: Ara-C
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    A549 IC50
    1.9 μM
    Compound: 2, Ara-C
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    [PMID: 24956556]
    A549 IC50
    1.9 μM
    Compound: 1, ara-C
    Cytotoxicity against human A549 cells by sulforhodamine B method
    Cytotoxicity against human A549 cells by sulforhodamine B method
    [PMID: 19691349]
    A549 IC50
    3.47 μM
    Compound: ara-C
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    A549 IC50
    49.27 μg/mL
    Compound: CAR
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 35963130]
    A549 IC50
    620 μM
    Compound: cytarabine
    Cytotoxicity against A549 cells after 72 hrs by SRB assay
    Cytotoxicity against A549 cells after 72 hrs by SRB assay
    [PMID: 17419604]
    B16 IC50
    30.62 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    B16 IC50
    49.22 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    BALL-1 GI50
    0.08 μM
    Compound: Ara-C
    Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
    Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    Bel-7402 IC50
    34.2 μM
    Compound: Ara-C
    Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay
    [PMID: 20692841]
    CCRF S-180 ED50
    0.2 μM
    Compound: ara-C
    Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation
    [PMID: 1652024]
    CCRF S-180 IC50
    25.43 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    CCRF S-180 IC50
    40.33 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    CCRF-CEM IC50
    0.001 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay
    [PMID: 19674903]
    CCRF-CEM EC50
    0.005614 μM
    Compound: cytarabine
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    CCRF-CEM IC50
    0.006 μM
    Compound: Ara-C
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay
    [PMID: 22582991]
    CCRF-CEM ED50
    0.006 μM
    Compound: ara-C
    Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation
    [PMID: 1652024]
    CCRF-CEM EC50
    0.0228 μM
    Compound: cytarabine
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    CCRF-CEM IC50
    0.024 μM
    Compound: cytarabine
    Cytotoxicity against human CEM cells after 2 days
    Cytotoxicity against human CEM cells after 2 days
    [PMID: 19910080]
    CCRF-CEM IC50
    0.024 μM
    Compound: ara-C, cytarabine
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs
    [PMID: 20000418]
    CCRF-HSB-2 IC50
    0.017 μg/mL
    Compound: AraC
    Growth inhibition of human CCRF-HSB-2 cells by MTT method
    Growth inhibition of human CCRF-HSB-2 cells by MTT method
    [PMID: 18819815]
    CCRF-HSB-2 IC50
    0.017 μg/mL
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    [PMID: 18723355]
    CCRF-HSB-2 IC50
    0.047 μg/mL
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
    Antitumor activity against human CCRF-HSB2 cells by modified MTT assay
    [PMID: 17644399]
    CCRF-HSB-2 IC50
    0.047 μg/mL
    Compound: Ara-C
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    Antitumor activity against human CCRF-HSB2 cells by MTT assay
    [PMID: 17962027]
    CCRF-HSB-2 IC50
    0.15 μM
    Compound: ara-C
    Growth inhibition of human CCRF-HSB-2 cells by MTT assay
    Growth inhibition of human CCRF-HSB-2 cells by MTT assay
    [PMID: 17049252]
    H22 IC50
    25.98 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    H22 IC50
    37.82 μM
    Compound: Cytarabine
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    HCT-116 IC50
    0.1 μM
    Compound: Ara-C
    Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
    Antitumor activity against human HCT116 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    HCT-116 GI50
    0.12 μM
    Compound: Ara-C
    Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
    Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    HCT-116 IC50
    2.42 μM
    Compound: Ara-C
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    HCT-116 IC50
    4.4 μM
    Compound: Ara-C
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    HCT-116 IC50
    5.3 μM
    Compound: 2, Ara-C
    Cytotoxicity against human HCT116 cells by SRB assay
    Cytotoxicity against human HCT116 cells by SRB assay
    [PMID: 24956556]
    HCT-116 IC50
    5.3 μM
    Compound: 1, ara-C
    Cytotoxicity against human HCT116 cells by sulforhodamine B method
    Cytotoxicity against human HCT116 cells by sulforhodamine B method
    [PMID: 19691349]
    HeLa ED50
    0.05 μg/mL
    Compound: AraC
    Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
    Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis
    [PMID: 178873]
    HeLa GI50
    0.18 μM
    Compound: Ara-C
    Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
    Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    HeLa IC50
    0.26 μM
    Compound: ara-C, cytarabine
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs
    [PMID: 20000418]
    HeLa IC50
    3.54 μM
    Compound: ara-C
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    HeLa IC50
    3.54 μM
    Compound: Cytarabine
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    [PMID: 27073055]
    HeLa IC50
    3.54 μM
    Compound: Cytarabine
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    Cytotoxicity against human HeLa cells after 72 hrs by SRB assay
    [PMID: 23867603]
    HeLa IC50
    3.54 μM
    Compound: ara-C
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    HeLa IC50
    464.433 μM
    Compound: Ara-C, Cytarabine
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    [PMID: 19321234]
    HeLa S3 ED50
    2.13 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    HepG2 IC50
    0.2 μM
    Compound: Ara-C
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    [PMID: 20692841]
    HepG2 IC50
    2.86 μM
    Compound: ara-C
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    HepG2 IC50
    2.86 μM
    Compound: Cytarabine
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay
    [PMID: 27073055]
    HepG2 IC50
    2.86 μM
    Compound: ara-C
    Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    HepG2 IC50
    26.23 μM
    Compound: Cytarabine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    HepG2 IC50
    38.1 μM
    Compound: Cytarabine
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    HL-60 IC50
    0.049 μM
    Compound: Ara-C
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    [PMID: 22582991]
    HL-60 IC50
    0.118 μM
    Compound: Ara-C, Cytarabine
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    [PMID: 19321234]
    HL-60 EC50
    0.6572 μM
    Compound: cytarabine
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    HL60/MX2 EC50
    0.2612 μM
    Compound: cytarabine
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay
    [PMID: 19743858]
    HT-29 IC50
    66 nM
    Compound: cytosine arabinoside
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
    [PMID: 2778449]
    HUVEC GI50
    0.23 μM
    Compound: Ara-C
    Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
    Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay
    [PMID: 22264170]
    K562 IC50
    0.05 μM
    Compound: 2, Ara-C
    Cytotoxicity against human K562 cells by SRB assay
    Cytotoxicity against human K562 cells by SRB assay
    [PMID: 24956556]
    K562 IC50
    0.05 μM
    Compound: 1, ara-C
    Cytotoxicity against human K562 cells by sulforhodamine B method
    Cytotoxicity against human K562 cells by sulforhodamine B method
    [PMID: 19691349]
    K562 IC50
    14 μM
    Compound: Ara-C
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay
    [PMID: 22582991]
    K562 IC50
    24.29 μM
    Compound: Cytarabine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    [PMID: 21620529]
    K562 IC50
    33.5 μM
    Compound: Ara-C
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    Cytotoxicity against human K562 cells after 24 hrs by MTT assay
    [PMID: 20692841]
    K562 IC50
    43.61 μM
    Compound: Cytarabine
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    10.1039/C0MD00208A
    KB IC50
    0.14 μg/mL
    Compound: Ara-C
    Growth inhibition of human KB cells by MTT assay
    Growth inhibition of human KB cells by MTT assay
    [PMID: 18055068]
    KB IC50
    0.23 μg/mL
    Compound: Ara-C
    Antitumor activity against human KB cells by modified MTT assay
    Antitumor activity against human KB cells by modified MTT assay
    [PMID: 17644399]
    KB IC50
    0.23 μg/mL
    Compound: Ara-C
    Antitumor activity against human KB cells by MTT assay
    Antitumor activity against human KB cells by MTT assay
    [PMID: 17962027]
    KB IC50
    0.42 μg/mL
    Compound: AraC
    Growth inhibition of human KB cells by MTT method
    Growth inhibition of human KB cells by MTT method
    [PMID: 18819815]
    KB IC50
    0.7 μM
    Compound: ara-C
    Growth inhibition of human KB cells by MTT assay
    Growth inhibition of human KB cells by MTT assay
    [PMID: 17049252]
    KB IC50
    0.73 μg/mL
    Compound: Ara-C
    Antitumor activity against human KB cells by MTT assay
    Antitumor activity against human KB cells by MTT assay
    [PMID: 18723355]
    KB IC50
    0.99 μg/mL
    Compound: Cytarabine
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    [PMID: 21945463]
    KB ED50
    2.84 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    KB IC50
    4.07 μM
    Compound: ara-C
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    KB IC50
    4.07 μM
    Compound: Cytarabine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    [PMID: 27073055]
    KB IC50
    4.07 μM
    Compound: Cytarabine
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    [PMID: 23867603]
    KB IC50
    4.07 μM
    Compound: ara-C
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    L02 IC50
    0.17 μM
    Compound: ARA
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 29886320]
    L02 IC50
    0.21 μM
    Compound: ARA
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay
    [PMID: 30852384]
    L1210 IC50
    0.0004 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay
    [PMID: 19674903]
    L1210 IC50
    0.024 μM
    Compound: cytarabine
    Cytotoxicity against mouse L1210 cells after 2 days
    Cytotoxicity against mouse L1210 cells after 2 days
    [PMID: 19910080]
    L1210 IC50
    0.024 μM
    Compound: ara-C, cytarabine
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
    Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs
    [PMID: 20000418]
    L1210 ED50
    0.05 μM
    Compound: ara-C
    Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation
    [PMID: 1652024]
    L1210 ED50
    0.1 μM
    Compound: ara-C
    Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
    Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay
    [PMID: 118258]
    L1210 ED50
    0.19 μM
    Compound: ara-C
    In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
    In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.
    [PMID: 3968680]
    L1210 IC50
    103 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
    Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay
    [PMID: 19674903]
    L1210 ED50
    2.76 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    MCF7 IC50
    > 20 μM
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay
    [PMID: 35665692]
    MCF7 IC50
    ≥ 100 μM
    Compound: Ara-C
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    Antitumor activity against human MCF7 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    MCF7 IC50
    0.004 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay
    [PMID: 19674903]
    MCF7 IC50
    0.04 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay
    [PMID: 19674903]
    MCF7 IC50
    0.93 μg/mL
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
    [PMID: 21945463]
    MCF7 IC50
    3.82 μM
    Compound: Cytarabine
    Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7cells after 72 hrs by SRB assay
    [PMID: 27073055]
    MCF7 IC50
    3.82 μM
    Compound: Cytarabine
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    [PMID: 23867603]
    MCF7 IC50
    3.82 μM
    Compound: ara-C
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    MDA-MB-231 IC50
    1.37 μM
    Compound: Ara-C
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    MDA-MB-231 IC50
    10.49 μM
    Compound: Ara-C
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    MES-SA IC50
    1.7 μM
    Compound: AraC, cytarabine
    Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
    Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay
    [PMID: 19674903]
    MOLT-3 ED50
    2.67 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    MOLT-4 IC50
    1 μM
    Compound: Ara-C
    Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
    Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    MV4-11 IC50
    3.36 μM
    Compound: AraC
    Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
    Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay
    [PMID: 20153646]
    NCI-H460 IC50
    0.1 μM
    Compound: Ara-C
    Antitumor activity against human H460 cells after 24 hrs by MTT assay
    Antitumor activity against human H460 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    NHDF IC50
    4.99 μM
    Compound: ara-C
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    NHDF IC50
    4.99 μM
    Compound: ara-C
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
    [PMID: 27501415]
    NUGC-3 GI50
    0.25 μM
    Compound: Ara-C
    Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
    Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay
    [PMID: 22264170]
    P388 ED50
    0.02 μM
    Compound: ara-C
    Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
    Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation
    [PMID: 1652024]
    P388 IC50
    1233 nM
    Compound: cytosine arabinoside
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
    [PMID: 2778449]
    PC-3 IC50
    0.81 μM
    Compound: ara-C
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    PC-3 IC50
    48.4 μM
    Compound: Ara-C
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    PC-3 IC50
    50.51 μM
    Compound: Ara-C
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    PC-3 IC50
    55.9 μM
    Compound: 2, Ara-C
    Cytotoxicity against human PC3 cells by SRB assay
    Cytotoxicity against human PC3 cells by SRB assay
    [PMID: 24956556]
    PC-3 IC50
    55.9 μM
    Compound: 1, ara-C
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    [PMID: 19691349]
    RS4-11 IC50
    0.26 μM
    Compound: AraC
    Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
    Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay
    [PMID: 20153646]
    SF-268 IC50
    7.68 nM
    Compound: Cytarabine
    Cytotoxicity against human SF268 cells by MTT assay
    Cytotoxicity against human SF268 cells by MTT assay
    [PMID: 19345581]
    SF-268 IC50
    7.68 μM
    Compound: Cytarabine
    Cytotoxicity against human SF268 cells after 3 days by MTT assay
    Cytotoxicity against human SF268 cells after 3 days by MTT assay
    [PMID: 20356655]
    SK-BR-3 IC50
    0.87 μM
    Compound: ara-C
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    SK-HEP1 IC50
    1.8 μM
    Compound: Ara-C
    Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    SK-HEP1 IC50
    2.12 μM
    Compound: Ara-C
    Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    SK-OV-3 IC50
    0.99 μM
    Compound: ara-C
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    SMMC-7721 IC50
    0.013 μM
    Compound: ARA
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 29886320]
    SMMC-7721 IC50
    0.0271 μM
    Compound: ARA
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay
    [PMID: 30852384]
    SNU-638 IC50
    0.15 μM
    Compound: 2, Ara-C
    Cytotoxicity against human SNU638 cells by SRB assay
    Cytotoxicity against human SNU638 cells by SRB assay
    [PMID: 24956556]
    SNU-638 IC50
    0.15 μM
    Compound: 1, ara-C
    Cytotoxicity against human SNU638 cells by sulforhodamine B method
    Cytotoxicity against human SNU638 cells by sulforhodamine B method
    [PMID: 19691349]
    SNU-638 IC50
    1.08 μM
    Compound: Ara-C
    Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay
    [PMID: 29906687]
    SNU-638 IC50
    3.98 μM
    Compound: Ara-C
    Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay
    [PMID: 26010585]
    SW1573 IC50
    10500 μM
    Compound: cytarabine
    Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
    Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
    [PMID: 17419604]
    SW480 ED50
    3.42 μg/mL
    Compound: cytosine arabinoside
    Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
    Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique
    [PMID: 1800632]
    SW-620 IC50
    30 μM
    Compound: Ara-C
    Antitumor activity against human SW620 cells after 24 hrs by MTT assay
    Antitumor activity against human SW620 cells after 24 hrs by MTT assay
    [PMID: 20211564]
    T47D IC50
    2.7 μM
    Compound: 1, ara-C
    Cytotoxicity against human T47D cells by sulforhodamine B method
    Cytotoxicity against human T47D cells by sulforhodamine B method
    [PMID: 19691349]
    T47D IC50
    2.72 μM
    Compound: 2, Ara-C
    Cytotoxicity against human T47D cells by SRB assay
    Cytotoxicity against human T47D cells by SRB assay
    [PMID: 24956556]
    U-87MG ATCC CC50
    0.19 μM
    Compound: 16
    Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
    Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay
    [PMID: 35123007]
    U-87MG ATCC IC50
    0.85 μM
    Compound: ara-C
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    U-87MG ATCC IC50
    2.88 μM
    Compound: ara-C
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    [PMID: 31400940]
    U-937 IC50
    0.002 μM
    Compound: Cytarabine
    Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
    Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay
    [PMID: 30954427]
    Vero EC50
    1.6 μg/mL
    Compound: Ara-C
    Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    [PMID: 12444692]
    Vero EC50
    3 μg/mL
    Compound: Ara-C
    Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay
    [PMID: 12444692]
    Vero CC50
    4.8 μg/mL
    Compound: Ara-C
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay
    [PMID: 12444692]
    WI-38 IC50
    > 100 μg/mL
    Compound: CAR
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay
    [PMID: 35963130]
    體外研究
    (In Vitro)

    Cytarabine is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM[1]. Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    體內(nèi)研究
    (In Vivo)

    Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity[3]. Cytarabine is highly effective against acute leukaemias, which causes the chCytarabineteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    279.68

    Formula

    C9H14ClN3O5

    CAS 號(hào)
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    鹽酸阿糖胞苷

    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.

    儲(chǔ)存方式

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn): 

    DMSO 中的溶解度 : 50 mg/mL (178.78 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開封的 DMSO)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.5755 mL 17.8776 mL 35.7551 mL
    5 mM 0.7151 mL 3.5755 mL 7.1510 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
    儲(chǔ)備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn):

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用;
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (8.94 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請(qǐng)依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.94 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

      2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。
    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息:

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    由于實(shí)驗(yàn)過程有損耗,建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購(gòu)。 ,Tween 80,均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度,以下方案僅供參考,如有需要,請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上,請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.67%

    參考文獻(xiàn)
    Animal Administration
    [3]

    Pregnant rats are injected intraperitoneally (i.p.) with 250 mg/kg of Cytarabine on Day 13 of gestation (GD13). Under the conditions of this experiment, congenital anomalies and growth retardation are detected at a high rate in perinatal fetuses, although the incidence of fetal death is not markedly increased. At 1, 3, 6, 9, 12, 24, and 48 h after the treatment, six dams each are killed by heart puncture under ether anesthesia, and the placentas are collected. As controls, six pregnant rats are injected i.p. with an equivalent volume of PBS on GD13 and killed at the same time point as Cytarabine-treated groups. Of the six dams obtained at each time point, three are used for histopathological analyses and three for reverse transcription-polymerase chain reaction (RT-PCR) analysis.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
    儲(chǔ)備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5755 mL 17.8776 mL 35.7551 mL 89.3879 mL
    5 mM 0.7151 mL 3.5755 mL 7.1510 mL 17.8776 mL
    10 mM 0.3576 mL 1.7878 mL 3.5755 mL 8.9388 mL
    15 mM 0.2384 mL 1.1918 mL 2.3837 mL 5.9592 mL
    20 mM 0.1788 mL 0.8939 mL 1.7878 mL 4.4694 mL
    25 mM 0.1430 mL 0.7151 mL 1.4302 mL 3.5755 mL
    30 mM 0.1192 mL 0.5959 mL 1.1918 mL 2.9796 mL
    40 mM 0.0894 mL 0.4469 mL 0.8939 mL 2.2347 mL
    50 mM 0.0715 mL 0.3576 mL 0.7151 mL 1.7878 mL
    60 mM 0.0596 mL 0.2980 mL 0.5959 mL 1.4898 mL
    80 mM 0.0447 mL 0.2235 mL 0.4469 mL 1.1173 mL
    100 mM 0.0358 mL 0.1788 mL 0.3576 mL 0.8939 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱:

     

    * 需求量:

    * 客戶姓名:

     

    * Email:

    * 電話:

     

    * 公司或機(jī)構(gòu)名稱:

       留言給我們:

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱:
    Cytarabine hydrochloride
    目錄號(hào):
    HY-13605A
    需求量: